Skip to main content
. 2012 Dec 1;13(14):1471–1481. doi: 10.4161/cbt.22254

Table 1. Histological and immunohistochemical evaluation of HCT-116- and HT-29-driven colorectal tumors based on the data represented in Figures 5, 6, 7 and 8.

 
 Tumor regression
 p-ERK
 p-MK2
 Tunel
HCT-116
Vehicle
 1
 1–2
 4
 1
SB202190
 2
 2
 3
 2
Sorafenib
 3
 0–1
 3
 2
SB202190+Sorafenib 5 1 1 3
HT-29
Vehicle
 1
 1
 4
 2
SB202190
 1–2
 1–2
 3
 2
Sorafenib
 2
 0–1
 2–3
 3
SB202190+Sorafenib 3 0 2 4

Score: 5 = max; 0 = min.